Pathophysiology Quiz: Pulmonary Hypertension
20 questions · exam conditions
0:00
Pulmonary HypertensionQuestion 1 of 20

A loss-of-function mutation in the bone morphogenetic protein receptor type 2 (BMPR2) gene is the most common genetic cause of heritable pulmonary arterial hypertension. This genetic defect primarily disrupts a signaling pathway that normally serves to:

Mediate potent hypoxic pulmonary vasoconstriction.
Inhibit proliferation and promote apoptosis of vascular smooth muscle cells.
Stimulate the synthesis of endothelin-1 by endothelial cells.
Enhance the degradation of cyclic GMP by phosphodiesterase-5.
← Back to quizzes

Pathophysiology Quiz

Pathophysiology Quiz: Pulmonary Hypertension

Practice Pulmonary Hypertension in Pathophysiology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Pulmonary Hypertension, giving you a quick way to practice the rules, question types, and explanations that matter most for Pathophysiology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A loss-of-function mutation in the bone morphogenetic protein receptor type 2 (BMPR2) gene is the most common genetic cause of heritable pulmonary arterial hypertension. This genetic defect primarily disrupts a signaling pathway that normally serves to:

  1. Mediate potent hypoxic pulmonary vasoconstriction.
  2. Inhibit proliferation and promote apoptosis of vascular smooth muscle cells. (correct answer)
  3. Stimulate the synthesis of endothelin-1 by endothelial cells.
  4. Enhance the degradation of cyclic GMP by phosphodiesterase-5.
Explanation: The BMPR2 signaling pathway plays a crucial role in maintaining vascular homeostasis. When activated by its ligands (like BMPs), it triggers a cascade that inhibits the growth and promotes the programmed cell death (apoptosis) of pulmonary artery smooth muscle cells. A loss-of-function mutation removes this 'brake,' leading to an over-proliferation of these cells and contributing to vascular remodeling.

Question 2

Perivascular inflammatory infiltrates are a common finding in the remodeled pulmonary arteries of patients with idiopathic PAH. These immune cells are thought to directly contribute to the progression of vascular remodeling primarily by:

  1. Depositing immune complexes that physically obstruct the vessel lumen.
  2. Secreting large amounts of nitric oxide, which paradoxically increases shear stress.
  3. Causing widespread destruction of the medial elastic fibers, leading to aneurysm formation.
  4. Releasing cytokines and growth factors that stimulate smooth muscle cell proliferation. (correct answer)
Explanation: When you encounter questions about pulmonary arterial hypertension (PAH), focus on the inflammatory cascade that drives progressive vascular remodeling. PAH isn't just a mechanical obstruction problem—it's fundamentally an inflammatory disease where immune cells orchestrate pathological changes in vessel structure. The correct answer is D because perivascular inflammatory infiltrates, including macrophages, T-cells, and dendritic cells, act as biological factories producing pro-inflammatory cytokines (like IL-1β, TNF-α) and growth factors (such as PDGF, TGF-β). These signaling molecules directly stimulate pulmonary artery smooth muscle cells to proliferate and migrate, creating the characteristic medial hypertrophy seen in PAH. This inflammatory-proliferative axis is the primary mechanism driving disease progression. Option A is incorrect because immune complexes don't physically obstruct vessels in PAH—the obstruction comes from cellular proliferation and remodeling. Option B misrepresents nitric oxide's role; inflammatory cells in PAH actually reduce NO bioavailability, and NO decreases rather than increases shear stress through vasodilation. Option C describes aneurysm pathology, which is opposite to PAH where vessels undergo concentric narrowing, not dilatation from elastic fiber destruction. For pathophysiology exams, remember that PAH questions often test your understanding of the inflammatory-proliferative connection. When you see "inflammatory infiltrates" plus "vascular remodeling," immediately think about cytokines and growth factors as the molecular bridge between inflammation and smooth muscle proliferation. This pattern appears frequently in cardiovascular pathophysiology.

Question 3

In certain endemic areas, infection with Schistosoma species is a major cause of pulmonary arterial hypertension. What is the primary initiating event in the pathogenesis of this specific form of PH?

  1. Direct obstruction of major pulmonary arteries by adult worms.
  2. A systemic autoimmune response to the parasite with antibodies that cross-react with endothelial cells.
  3. Development of severe liver cirrhosis, leading to portopulmonary hypertension.
  4. Embolization of parasite eggs to the pulmonary microvasculature, inducing a granulomatous reaction. (correct answer)
Explanation: When you encounter questions about schistosomiasis-induced pulmonary hypertension, focus on the parasite's life cycle and where pathology occurs. Schistosoma eggs are the key pathogenic agents, not the adult worms themselves. The correct answer is D because schistosomiasis-associated pulmonary arterial hypertension begins when parasite eggs embolize from the systemic circulation into pulmonary arterioles and capillaries. These eggs become trapped in the small vessels and trigger intense granulomatous inflammation as the immune system attempts to contain them. This granulomatous reaction causes vessel wall thickening, luminal narrowing, and progressive vascular remodeling, ultimately leading to increased pulmonary vascular resistance and pulmonary hypertension. Option A is incorrect because adult Schistosoma worms live in mesenteric or vesical veins, not pulmonary arteries, and don't directly obstruct major vessels. Option B misrepresents the mechanism - while there is an immune response, it's primarily a local granulomatous reaction to trapped eggs rather than systemic autoimmunity with cross-reactive antibodies. Option C describes portopulmonary hypertension, which can occur with schistosomiasis but represents a secondary mechanism through portal hypertension and liver disease, not the primary pathway of schistosomiasis-associated PAH. Remember that in parasitic diseases, the location where eggs or larvae get trapped often determines the primary pathology. For schistosomiasis and pulmonary hypertension, think "eggs trapped in lungs = granulomas = vascular remodeling = PAH." This egg embolization mechanism is what makes schistosomiasis a direct cause of Group 1 pulmonary arterial hypertension in endemic regions.

Question 4

A patient with known portal hypertension due to liver cirrhosis develops portopulmonary hypertension. The mechanism is multifactorial but is thought to involve vasoactive substances from the splanchnic circulation that bypass hepatic metabolism. This leads to a vascular pathology most similar to which other WHO Group of pulmonary hypertension?

  1. Group 1 (Idiopathic PAH) (correct answer)
  2. Group 2 (PH due to Left Heart Disease)
  3. Group 3 (PH due to Lung Disease)
  4. Group 4 (CTEPH)
Explanation: Portopulmonary hypertension is classified under WHO Group 1. Although triggered by liver disease, the resulting pulmonary vascular disease is histopathologically indistinguishable from idiopathic PAH. It is a pre-capillary process characterized by vasoconstriction, smooth muscle and endothelial cell proliferation, and remodeling of the pulmonary arterioles, likely due to an imbalance of circulating vasoactive mediators that have bypassed first-pass metabolism in the damaged liver.

Question 5

The pathophysiology of Group 1 pulmonary arterial hypertension (PAH) is characterized by a critical imbalance in locally produced vasoactive mediators. A key feature of this imbalance is the deficient production of which two substances, contributing to a pro-vasoconstrictive and pro-proliferative state?

  1. Endothelin-1 and Angiotensin II
  2. Nitric oxide and Prostacyclin (correct answer)
  3. Thromboxane A2 and Serotonin
  4. Bradykinin and Vasoactive Intestinal Peptide
Explanation: In PAH, endothelial dysfunction leads to reduced production of endogenous vasodilators. The most important of these are nitric oxide (NO), which acts via the cGMP pathway, and prostacyclin (PGI2), which acts via the cAMP pathway. Loss of these substances shifts the balance toward vasoconstriction and smooth muscle cell proliferation, which are driven by substances like endothelin-1 and thromboxane A2.

Question 6

A patient undergoes right heart catheterization with the following results: mean pulmonary artery pressure (mPAP) = 42 mmHg; pulmonary capillary wedge pressure (PCWP) = 12 mmHg; cardiac output (CO) = 4 L/min. What is the calculated pulmonary vascular resistance (PVR) in Wood units, and what does this pattern indicate?

  1. PVR = 13.5 Wood units, indicating combined pre- and post-capillary PH.
  2. PVR = 10.5 Wood units, indicating a high-flow state is the cause of PH.
  3. PVR = 7.5 Wood units, indicating a pre-capillary etiology with high arteriolar resistance. (correct answer)
  4. PVR = 3.0 Wood units, indicating isolated post-capillary PH with passive pressure transmission.
Explanation: Pulmonary vascular resistance (PVR) is calculated using the formula: PVR = (mPAP - PCWP) / CO. In this case, PVR = (42 - 12) / 4 = 30 / 4 = 7.5 Wood units. A PVR > 3 Wood units is considered elevated. Since the PCWP (a surrogate for left atrial pressure) is normal (≤ 15 mmHg) and the PVR is high, this pattern is characteristic of pre-capillary pulmonary hypertension, where the pathology lies within the pulmonary arterioles themselves.

Question 7

The mechanism of hypoxic pulmonary vasoconstriction (HPV) involves a direct sensing of low oxygen tension by pulmonary artery smooth muscle cells. The critical initiating intracellular event in this process is:

  1. Activation of ATP-sensitive K+ channels, leading to membrane hyperpolarization.
  2. Upregulation of endothelial nitric oxide synthase expression.
  3. Inhibition of voltage-gated K+ (Kv) channels, leading to membrane depolarization. (correct answer)
  4. Release of calcium from the sarcoplasmic reticulum triggered by reactive oxygen species.
Explanation: The consensus model for HPV initiation involves voltage-gated potassium (Kv) channels in the smooth muscle cell membrane. Hypoxia inhibits the function of these channels. Since K+ efflux through these channels normally helps keep the cell membrane hyperpolarized (negative), their inhibition leads to membrane depolarization. This depolarization activates voltage-gated L-type calcium channels, allowing calcium to enter the cell and trigger contraction.

Question 8

In pulmonary arterial hypertension, a vicious cycle develops where increased pressure and turbulent flow alter hemodynamic shear stress. This altered mechanical force on the endothelium primarily promotes disease progression by:

  1. Stimulating the endothelium to adopt a pro-inflammatory and pro-proliferative phenotype. (correct answer)
  2. Causing mechanical fatigue and rupture of the main pulmonary artery.
  3. Directly activating latent fibroblasts in the adventitia to begin collagen synthesis.
  4. Triggering a baroreceptor reflex that leads to systemic hypertension.
Explanation: Endothelial cells are highly sensitive to shear stress. Normal, laminar flow promotes a quiescent, anti-inflammatory, anti-thrombotic state. The turbulent, high-pressure flow in PAH creates abnormal shear stress, which causes the endothelial cells to switch to an activated phenotype. They begin to express adhesion molecules (recruiting inflammatory cells), release pro-proliferative factors, and downregulate the production of protective vasodilators like nitric oxide, thereby exacerbating the very conditions that caused the altered flow.

Question 9

Histopathological examination of lung tissue from a patient with end-stage idiopathic pulmonary arterial hypertension is most likely to reveal which finding that represents a hallmark of advanced, irreversible vascular remodeling?

  1. Medial hypertrophy of muscular pulmonary arteries.
  2. Concentric, 'onion-skin' intimal fibrosis.
  3. Plexiform lesions with tufts of proliferating endothelial cells. (correct answer)
  4. Perivascular infiltrates of lymphocytes and macrophages.
Explanation: While medial hypertrophy, intimal fibrosis, and inflammation are all features of PAH, the plexiform lesion is considered the pathognomonic finding of advanced disease. It is a complex structure arising from uncontrolled, disorganized proliferation of endothelial cells and other cells within the vessel lumen, often bypassing the obstructed parent artery, and it signifies a late and irreversible stage of the disease.

Question 10

A patient with systemic sclerosis (scleroderma) develops severe pulmonary arterial hypertension. The pathogenesis in this specific condition is believed to be initiated by an autoimmune-mediated vasculopathy. This primary event triggers a pathological cascade best characterized by:

  1. Chronic hypoxic vasoconstriction secondary to co-existing interstitial lung disease.
  2. Passive venous congestion from scleroderma-related restrictive cardiomyopathy and left ventricular dysfunction.
  3. Recurrent thromboembolism from a hypercoagulable state associated with chronic inflammation.
  4. Endothelial cell injury and apoptosis, leading to an overproduction of endothelin-1 and a loss of nitric oxide. (correct answer)
Explanation: When you encounter questions about systemic sclerosis and pulmonary arterial hypertension (PAH), focus on the underlying autoimmune vasculopathy that distinguishes this condition from other forms of pulmonary hypertension. In scleroderma-associated PAH, autoimmune mechanisms directly target the pulmonary vasculature, creating a specific pathological cascade. The autoimmune attack causes endothelial cell injury and apoptosis in pulmonary arteries. This endothelial dysfunction disrupts the delicate balance of vasoactive mediators: damaged endothelial cells overproduce the potent vasoconstrictor endothelin-1 while losing their ability to produce nitric oxide, a crucial vasodilator. This imbalance leads to progressive vasoconstriction, vascular remodeling, and ultimately severe PAH. Answer D correctly describes this primary pathogenic mechanism. Answer A incorrectly suggests that hypoxic vasoconstriction from interstitial lung disease is the primary mechanism. While some scleroderma patients develop interstitial fibrosis, PAH in systemic sclerosis can occur independently and is primarily driven by autoimmune vasculopathy, not hypoxia. Answer B misidentifies the problem as passive venous congestion from left heart disease. Scleroderma-associated PAH is a pre-capillary pulmonary hypertension affecting the arterial side, not a post-capillary condition from left ventricular dysfunction. Answer C focuses on thromboembolism, which characterizes chronic thromboembolic pulmonary hypertension (CTEPH), not the autoimmune-mediated PAH seen in systemic sclerosis. Remember: In autoimmune connective tissue diseases like scleroderma, always consider direct vascular injury as the primary mechanism rather than secondary effects from other organ involvement.

Question 11

The use of certain appetite-suppressant drugs (e.g., fenfluramine) was linked to a high incidence of pulmonary arterial hypertension. This association is thought to be mediated by alterations in serotonin (5-HT) signaling. What is the primary dual action of excess serotonin on the pulmonary vasculature that promotes PH?

  1. It inhibits endothelial cell apoptosis and stimulates nitric oxide production.
  2. It acts as a mitogen for smooth muscle cells and is a potent vasoconstrictor. (correct answer)
  3. It induces a pro-thrombotic state and degrades the elastic lamina of arteries.
  4. It recruits inflammatory cells and enhances collagen deposition in the adventitia.
Explanation: Serotonin has two major effects that contribute to the pathogenesis of pulmonary hypertension. First, it is a direct vasoconstrictor of pulmonary artery smooth muscle cells. Second, and perhaps more importantly, it is a potent mitogen, meaning it stimulates the proliferation of these cells. This combination of vasoconstriction and promotion of remodeling is a powerful driver of the disease.

Question 12

In-situ thrombosis is recognized as a contributing factor in the progression of pulmonary arterial hypertension, even in the absence of major emboli. What is the primary driver of this localized thrombotic tendency?

  1. A systemic hypercoagulable state caused by circulating pro-thrombotic factors.
  2. Profoundly sluggish blood flow within dilated, failing right heart chambers.
  3. Excessive platelet activation caused by high levels of circulating prostacyclin.
  4. Dysfunctional, pro-inflammatory endothelial cells that have lost their anticoagulant properties. (correct answer)
Explanation: When you encounter questions about pulmonary arterial hypertension (PAH) and thrombosis, focus on the local vascular environment rather than systemic factors. PAH creates a perfect storm for clot formation through endothelial dysfunction. In PAH, chronic pressure overload and inflammatory mediators transform the pulmonary endothelium from a protective, anticoagulant surface into a pro-thrombotic one. Healthy endothelial cells produce nitric oxide, prostacyclin, and tissue plasminogen activator while expressing anticoagulant proteins like thrombomodulin. When these cells become dysfunctional, they lose these protective properties and instead release pro-inflammatory cytokines, tissue factor, and von Willebrand factor—all promoting local clot formation. This creates a vicious cycle where thrombosis worsens pulmonary vascular resistance, further elevating pressures and perpetuating endothelial damage. Option A incorrectly suggests systemic hypercoagulability, but PAH patients don't typically have generalized clotting disorders—the thrombosis is localized to damaged pulmonary vessels. Option B mentions sluggish flow in the right heart, but in-situ thrombosis occurs in the pulmonary arteries themselves, not the cardiac chambers. Option C contains a contradiction: prostacyclin is actually anticoagulant and typically decreased (not increased) in PAH. Remember that PAH pathophysiology centers on the pulmonary vascular endothelium. When you see questions about complications in PAH—whether thrombosis, vasoconstriction, or remodeling—think about how endothelial dysfunction drives these processes locally rather than looking for systemic explanations.

Question 13

A patient with idiopathic pulmonary arterial hypertension (PAH) is treated with bosentan, an endothelin receptor antagonist. This therapy is primarily intended to counteract which of the following downstream cellular effects of endothelin-1 (ET-1) in the pulmonary arteries?

  1. Potent vasoconstriction and mitogenesis of vascular smooth muscle cells. (correct answer)
  2. Increased synthesis of prostacyclin and nitric oxide by endothelial cells.
  3. Fibrotic organization of unresolved microthrombi within the vessel lumen.
  4. Apoptosis of endothelial cells and breakdown of the vessel basement membrane.
Explanation: Endothelin-1 (ET-1) is a potent vasoconstrictor and a mitogen that stimulates the proliferation of pulmonary artery smooth muscle cells. Both of these actions contribute significantly to the increased pulmonary vascular resistance and vascular remodeling seen in PAH. Endothelin receptor antagonists like bosentan block these effects, leading to vasodilation and reduced proliferation.

Question 14

In severe pulmonary arterial hypertension, sustained and severe pressure overload on the right ventricle (RV) leads to a transition from compensated hypertrophy to decompensated failure. This transition is pathophysiologically marked by:

  1. A progressive decrease in RV wall thickness as myocyte apoptosis exceeds hypertrophy.
  2. The development of severe tricuspid stenosis, which limits RV filling.
  3. An inability of the RV to maintain stroke volume, leading to cavity dilation and increased wall stress. (correct answer)
  4. A paradoxical decrease in pulmonary artery pressures as the RV fails and cardiac output drops.
Explanation: Initially, the RV compensates for high afterload by undergoing hypertrophy (thickening of its wall). However, as afterload remains critically high, the ventricle's intrinsic contractility can no longer overcome the resistance. It fails to eject blood effectively, leading to an increase in end-systolic volume and subsequent dilation of the chamber. According to the Law of Laplace, this dilation increases wall stress, further impairing function and creating a vicious cycle of failure.

Question 15

In pulmonary arterial hypertension, a vicious cycle develops where increased pressure and turbulent flow alter hemodynamic shear stress. This altered mechanical force on the endothelium primarily promotes disease progression by:

  1. Stimulating the endothelium to adopt a pro-inflammatory and pro-proliferative phenotype. (correct answer)
  2. Causing mechanical fatigue and rupture of the main pulmonary artery.
  3. Directly activating latent fibroblasts in the adventitia to begin collagen synthesis.
  4. Triggering a baroreceptor reflex that leads to systemic hypertension.
Explanation: Endothelial cells are highly sensitive to shear stress. Normal, laminar flow promotes a quiescent, anti-inflammatory, anti-thrombotic state. The turbulent, high-pressure flow in PAH creates abnormal shear stress, which causes the endothelial cells to switch to an activated phenotype. They begin to express adhesion molecules (recruiting inflammatory cells), release pro-proliferative factors, and downregulate the production of protective vasodilators like nitric oxide, thereby exacerbating the very conditions that caused the altered flow.

Question 16

A 70-year-old patient with long-standing, severe mitral stenosis develops pulmonary hypertension. The primary hemodynamic mechanism responsible for this patient's condition is:

  1. A primary obliterative vasculopathy of the pulmonary arterioles.
  2. Chronic hypoxic vasoconstriction due to impaired gas exchange.
  3. Chronically elevated left atrial pressure transmitting passively to the pulmonary circulation. (correct answer)
  4. Recurrent thromboembolism from a low-flow state in the left atrium.
Explanation: This scenario describes Group 2 pulmonary hypertension, or PH due to left heart disease. In mitral stenosis, the stiff mitral valve obstructs outflow from the left atrium, causing a significant rise in left atrial pressure. This pressure is transmitted backward through the pulmonary veins to the pulmonary capillaries and arteries, leading to post-capillary pulmonary hypertension.

Question 17

Histopathological examination of lung tissue from a patient with end-stage idiopathic pulmonary arterial hypertension is most likely to reveal which finding that represents a hallmark of advanced, irreversible vascular remodeling?

  1. Medial hypertrophy of muscular pulmonary arteries.
  2. Concentric, 'onion-skin' intimal fibrosis.
  3. Plexiform lesions with tufts of proliferating endothelial cells. (correct answer)
  4. Perivascular infiltrates of lymphocytes and macrophages.
Explanation: While medial hypertrophy, intimal fibrosis, and inflammation are all features of PAH, the plexiform lesion is considered the pathognomonic finding of advanced disease. It is a complex structure arising from uncontrolled, disorganized proliferation of endothelial cells and other cells within the vessel lumen, often bypassing the obstructed parent artery, and it signifies a late and irreversible stage of the disease.

Question 18

A loss-of-function mutation in the bone morphogenetic protein receptor type 2 (BMPR2) gene is the most common genetic cause of heritable pulmonary arterial hypertension. This genetic defect primarily disrupts a signaling pathway that normally serves to:

  1. Mediate potent hypoxic pulmonary vasoconstriction.
  2. Inhibit proliferation and promote apoptosis of vascular smooth muscle cells. (correct answer)
  3. Stimulate the synthesis of endothelin-1 by endothelial cells.
  4. Enhance the degradation of cyclic GMP by phosphodiesterase-5.
Explanation: The BMPR2 signaling pathway plays a crucial role in maintaining vascular homeostasis. When activated by its ligands (like BMPs), it triggers a cascade that inhibits the growth and promotes the programmed cell death (apoptosis) of pulmonary artery smooth muscle cells. A loss-of-function mutation removes this 'brake,' leading to an over-proliferation of these cells and contributing to vascular remodeling.

Question 19

The sustained elevation in pulmonary artery pressure in a patient with pulmonary hypertension secondary to interstitial lung disease (Group 3) results from a vicious cycle initiated by chronic alveolar hypoxia. This hypoxia promotes pathologic vascular remodeling primarily through:

  1. Directly stimulating fibroblast proliferation and collagen deposition in the vessel adventitia.
  2. Causing sustained vasoconstriction, which increases shear stress and promotes smooth muscle cell muscularization. (correct answer)
  3. Inducing a systemic inflammatory response that targets the pulmonary endothelium for destruction.
  4. Decreasing cardiac output, which leads to stasis and in-situ thrombosis within pulmonary arterioles.
Explanation: In Group 3 PH, chronic hypoxia is the main driver. The initial response is hypoxic pulmonary vasoconstriction. This sustained constriction becomes a stimulus for remodeling. The increased pressure and altered flow (shear stress) on the vessel wall, combined with hypoxia itself, signal smooth muscle cells to proliferate and hypertrophy, and for small, non-muscular arterioles to become muscularized, making the increased resistance permanent.

Question 20

A patient undergoes right heart catheterization with the following results: mean pulmonary artery pressure (mPAP) = 42 mmHg; pulmonary capillary wedge pressure (PCWP) = 12 mmHg; cardiac output (CO) = 4 L/min. What is the calculated pulmonary vascular resistance (PVR) in Wood units, and what does this pattern indicate?

  1. PVR = 13.5 Wood units, indicating combined pre- and post-capillary PH.
  2. PVR = 10.5 Wood units, indicating a high-flow state is the cause of PH.
  3. PVR = 7.5 Wood units, indicating a pre-capillary etiology with high arteriolar resistance. (correct answer)
  4. PVR = 3.0 Wood units, indicating isolated post-capillary PH with passive pressure transmission.
Explanation: Pulmonary vascular resistance (PVR) is calculated using the formula: PVR = (mPAP - PCWP) / CO. In this case, PVR = (42 - 12) / 4 = 30 / 4 = 7.5 Wood units. A PVR > 3 Wood units is considered elevated. Since the PCWP (a surrogate for left atrial pressure) is normal (≤ 15 mmHg) and the PVR is high, this pattern is characteristic of pre-capillary pulmonary hypertension, where the pathology lies within the pulmonary arterioles themselves.